PIEZO2 and carcinoma: With this interpretation, Piezo2 would have diminished expression in carcinomas, but its expression would be enhanced in moderately or highly proliferative carcinomas, as measured by the Ki67 immunostaining, in line with the findings of Katsuta et al. [25].